Author Title [ Type(Desc)] Year
Filters: Author is Lund, Troy C  [Clear All Filters]
Journal Article
Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014.
Musolino PL, Lund TC, Pan J, Escolar ML, Duncan CN, Eichler FS. Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A Systematic Review of the Literature. Neuropediatrics. 2014.
Lum SHan, Orchard PJ, Lund TC, Miller WP, Boelens JJan, Wynn R. Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome. Biol Blood Marrow Transplant. 2020.
Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, Davis JH, Dalal JD, Devine SM, Eames GM, et al. Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease. Biol Blood Marrow Transplant. 2014.
Lund TC, Ahn KWoo, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, Díaz MÁngel, Badawy SM, Broglie L, Brown V, et al. Outcomes After Second Hematopoietic Cell Transplant for Children and Young Adults with Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2018.
Gupta A, Downey M, Shanley R, Jennissen C, Miller WP, Lund TC, Orchard PJ, Smith AR. Reduced Toxicity (BuFlu) Conditioning Is Better Tolerated but Has Higher Second Transplant Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders. Biol Blood Marrow Transplant. 2019.
Lund TC, Patrinostro X, Kramer AC, Stadem P, Higgins L, Markowski TW, Wroblewski MS, Lidke DS, Tolar J, Blazar BR. sdf1 expression reveals a source of perivascular-derived mesenchymal stem cells in zebrafish. Stem Cells. 2014.